Telix Pharmaceuticals (NASDAQ:TLX) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Telix Pharmaceuticals (NASDAQ:TLX) in a report published on Monday,Benzinga reports. The brokerage currently has a $20.00 price objective on the stock.

TLX has been the topic of a number of other research reports. Wedbush reissued an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Tuesday, April 7th. Weiss Ratings restated a “sell (d)” rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Citigroup upped their target price on Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a “buy” rating in a research note on Tuesday, February 24th. Wall Street Zen upgraded Telix Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Royal Bank Of Canada upgraded Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a research note on Monday, January 19th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Telix Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $21.13.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ:TLX opened at $11.24 on Monday. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $20.00. The company has a debt-to-equity ratio of 1.08, a current ratio of 1.43 and a quick ratio of 1.27. The business’s 50 day simple moving average is $7.98 and its 200 day simple moving average is $8.71.

Telix Pharmaceuticals (NASDAQ:TLX) last issued its quarterly earnings results on Friday, February 20th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The company had revenue of $206.72 million during the quarter, compared to analyst estimates of $421.50 million. On average, sell-side analysts anticipate that Telix Pharmaceuticals will post 0.24 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rhumbline Advisers lifted its stake in shares of Telix Pharmaceuticals by 117.3% in the 3rd quarter. Rhumbline Advisers now owns 2,579 shares of the company’s stock valued at $25,000 after acquiring an additional 1,392 shares during the last quarter. XTX Topco Ltd bought a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at $89,000. IHT Wealth Management LLC bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at $213,000. OLD Mission Capital LLC bought a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at $111,000. Finally, JPMorgan Chase & Co. bought a new position in shares of Telix Pharmaceuticals in the 3rd quarter valued at $243,000.

Telix Pharmaceuticals News Roundup

Here are the key news stories impacting Telix Pharmaceuticals this week:

• Positive Sentiment: Telix and Regeneron announced a strategic radiopharmaceutical collaboration to jointly develop and commercialize next‑generation radiopharma therapies, targeting solid tumors; the deal carries potential development and commercial scale benefits and was reported with deal economics described as up to $2.1 billion in potential value. This is a major validation for Telix’s technology and expands commercialization reach. Telix and Regeneron Announce Strategic Radiopharma Collaboration
• Positive Sentiment: Market coverage and headlines highlighted the Regeneron tie-up and its focus on solid‑tumor programs, prompting buying interest and headlines that Telix shares “jumped” on the deal — reinforcing the near‑term positive market reaction. Telix Pharmaceuticals Shares Jump on Regeneron Deal
• Positive Sentiment: Analysts reiterated bullish ratings and high price targets after the news: Wedbush reaffirmed an “outperform” with a $22 target and HC Wainwright kept a “buy” with a $20 target — both imply substantial upside from current levels and support continued investor interest. Benzinga
• Neutral Sentiment: Citi group entities dropped below the substantial holder threshold in Telix, per filings — a change in reported institutional ownership that is noteworthy for monitoring but not necessarily an immediate directional signal for the stock. Citi Group Entities Drop Below Substantial Holder Threshold in Telix Pharmaceuticals

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals (NASDAQ: TLX) is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.